Table 1.
Patient characteristics
| Characteristic | Total |
|---|---|
| Gender | |
| Male | 10 (71%) |
| Female | 4 (29%) |
| Age, years | |
| Median [IQR] | 69 [61–73] |
| ECOG performance status | |
| 0 | 2 (14%) |
| 1 | 12 (86%) |
| Ethnic origin | |
| White | 14 (100%) |
| BMI, kg/m2 | |
| Median [IQR] | 28.6 [24.1–29.9] |
| eGFR, mL/minutea | |
| Median [IQR] | 82 [77–91] |
| Liver function (median [IQR]) | |
| AST | 39 [27–68] |
| ALT | 33 [17–39] |
| Bilirubin | 8 [6–13] |
| Prior therapy | |
| Surgery | 12 (86%) |
| Radiotherapy | 4 (29%) |
| Chemotherapy | 14 (100%) |
| Monoclonal antibodiesb | 9 (64%) |
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; eGFR, estimated glomerular filtration rate; IQR, interquartile range.
aeGFR was calculated according to the Chronic Kidney Disease Epidemiology Collaboration. bTreatment with monoclonal antibodies included bevacizumab, panitumumab, and cetuximab.